WO2004054570A1 - Combinations of medicaments comprising an alcohol deterrent for treating alcohol dependence or alcohol abuse - Google Patents
Combinations of medicaments comprising an alcohol deterrent for treating alcohol dependence or alcohol abuse Download PDFInfo
- Publication number
- WO2004054570A1 WO2004054570A1 PCT/CA2003/000990 CA0300990W WO2004054570A1 WO 2004054570 A1 WO2004054570 A1 WO 2004054570A1 CA 0300990 W CA0300990 W CA 0300990W WO 2004054570 A1 WO2004054570 A1 WO 2004054570A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical
- combination medicine
- alcohol
- disulfiram
- chosen
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 109
- 208000007848 Alcoholism Diseases 0.000 title claims description 14
- 206010001584 alcohol abuse Diseases 0.000 title claims description 10
- 208000025746 alcohol use disease Diseases 0.000 title claims description 10
- 201000007930 alcohol dependence Diseases 0.000 title description 4
- 239000003081 alcohol deterrent Substances 0.000 title description 2
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 claims abstract description 180
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 101
- 229960002563 disulfiram Drugs 0.000 claims abstract description 91
- 229940049706 benzodiazepine Drugs 0.000 claims abstract description 76
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims abstract description 52
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 36
- 230000036506 anxiety Effects 0.000 claims abstract description 29
- 230000000694 effects Effects 0.000 claims abstract description 15
- 229960004987 calcium carbimide Drugs 0.000 claims description 30
- MYFXBBAEXORJNB-UHFFFAOYSA-N calcium cyanamide Chemical compound [Ca+2].[N-]=C=[N-] MYFXBBAEXORJNB-UHFFFAOYSA-N 0.000 claims description 30
- 229960004047 acamprosate Drugs 0.000 claims description 28
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 claims description 28
- 229960003120 clonazepam Drugs 0.000 claims description 22
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 claims description 22
- 239000000935 antidepressant agent Substances 0.000 claims description 17
- 229940005513 antidepressants Drugs 0.000 claims description 13
- 230000000147 hypnotic effect Effects 0.000 claims description 13
- 239000000932 sedative agent Substances 0.000 claims description 13
- -1 oral solution Substances 0.000 claims description 11
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims description 10
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 10
- 239000003485 histamine H2 receptor antagonist Substances 0.000 claims description 10
- 206010022437 insomnia Diseases 0.000 claims description 10
- 229960001797 methadone Drugs 0.000 claims description 10
- 229940126409 proton pump inhibitor Drugs 0.000 claims description 10
- 239000000612 proton pump inhibitor Substances 0.000 claims description 10
- 208000002193 Pain Diseases 0.000 claims description 9
- 230000001430 anti-depressive effect Effects 0.000 claims description 9
- 239000002249 anxiolytic agent Substances 0.000 claims description 9
- 230000000949 anxiolytic effect Effects 0.000 claims description 9
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims description 8
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims description 8
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 8
- 230000001624 sedative effect Effects 0.000 claims description 8
- GBBSUAFBMRNDJC-MRXNPFEDSA-N (5R)-zopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-MRXNPFEDSA-N 0.000 claims description 7
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 claims description 7
- 229940005483 opioid analgesics Drugs 0.000 claims description 7
- KQPKPCNLIDLUMF-UHFFFAOYSA-N secobarbital Chemical compound CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O KQPKPCNLIDLUMF-UHFFFAOYSA-N 0.000 claims description 7
- 229960002060 secobarbital Drugs 0.000 claims description 7
- 208000011117 substance-related disease Diseases 0.000 claims description 7
- HUNXMJYCHXQEGX-UHFFFAOYSA-N zaleplon Chemical compound CCN(C(C)=O)C1=CC=CC(C=2N3N=CC(=C3N=CC=2)C#N)=C1 HUNXMJYCHXQEGX-UHFFFAOYSA-N 0.000 claims description 7
- 229960004010 zaleplon Drugs 0.000 claims description 7
- 229960000820 zopiclone Drugs 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 230000002939 deleterious effect Effects 0.000 claims description 6
- 206010013654 Drug abuse Diseases 0.000 claims description 5
- 208000000718 duodenal ulcer Diseases 0.000 claims description 5
- 230000002496 gastric effect Effects 0.000 claims description 5
- 239000003326 hypnotic agent Substances 0.000 claims description 5
- 229940125723 sedative agent Drugs 0.000 claims description 5
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims description 4
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 claims description 4
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims description 4
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 claims description 4
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 claims description 4
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 4
- 229940005530 anxiolytics Drugs 0.000 claims description 4
- 229960001380 cimetidine Drugs 0.000 claims description 4
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 claims description 4
- 229960004126 codeine Drugs 0.000 claims description 4
- 229960004193 dextropropoxyphene Drugs 0.000 claims description 4
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 claims description 4
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims description 4
- 229960004770 esomeprazole Drugs 0.000 claims description 4
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 claims description 4
- 229960001596 famotidine Drugs 0.000 claims description 4
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 claims description 4
- 230000037406 food intake Effects 0.000 claims description 4
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims description 4
- 229960000240 hydrocodone Drugs 0.000 claims description 4
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims description 4
- 229960001410 hydromorphone Drugs 0.000 claims description 4
- 229960003174 lansoprazole Drugs 0.000 claims description 4
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 claims description 4
- 229960005181 morphine Drugs 0.000 claims description 4
- 229960000381 omeprazole Drugs 0.000 claims description 4
- 229960002085 oxycodone Drugs 0.000 claims description 4
- 229960005118 oxymorphone Drugs 0.000 claims description 4
- 229960005019 pantoprazole Drugs 0.000 claims description 4
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 claims description 4
- 229960005301 pentazocine Drugs 0.000 claims description 4
- 229960000482 pethidine Drugs 0.000 claims description 4
- 229960004157 rabeprazole Drugs 0.000 claims description 4
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 claims description 4
- 229960000620 ranitidine Drugs 0.000 claims description 4
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 claims description 4
- 229940097693 Aldehyde dehydrogenase inhibitor Drugs 0.000 claims description 3
- 239000003187 aldehyde dehydrogenase inhibitor Substances 0.000 claims description 3
- 239000006189 buccal tablet Substances 0.000 claims description 3
- 206010015037 epilepsy Diseases 0.000 claims description 3
- 201000005917 gastric ulcer Diseases 0.000 claims description 3
- 229940100688 oral solution Drugs 0.000 claims description 3
- 239000006190 sub-lingual tablet Substances 0.000 claims description 3
- 239000000829 suppository Substances 0.000 claims description 3
- 229940046011 buccal tablet Drugs 0.000 claims description 2
- 229940098466 sublingual tablet Drugs 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- APXRHPDHORGIEB-UHFFFAOYSA-N 1H-pyrazolo[4,3-d]pyrimidine Chemical class N1=CN=C2C=NNC2=C1 APXRHPDHORGIEB-UHFFFAOYSA-N 0.000 claims 6
- 229940125717 barbiturate Drugs 0.000 claims 6
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 claims 3
- 239000002899 monoamine oxidase inhibitor Substances 0.000 claims 3
- 150000003335 secondary amines Chemical class 0.000 claims 3
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims 2
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 claims 2
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 claims 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims 2
- VMIYHDSEFNYJSL-UHFFFAOYSA-N Bromazepam Chemical compound C12=CC(Br)=CC=C2NC(=O)CN=C1C1=CC=CC=N1 VMIYHDSEFNYJSL-UHFFFAOYSA-N 0.000 claims 2
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 claims 2
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 claims 2
- WYCLKVQLVUQKNZ-UHFFFAOYSA-N Halazepam Chemical compound N=1CC(=O)N(CC(F)(F)F)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 WYCLKVQLVUQKNZ-UHFFFAOYSA-N 0.000 claims 2
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 claims 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims 2
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 claims 2
- MWQCHHACWWAQLJ-UHFFFAOYSA-N Prazepam Chemical compound O=C1CN=C(C=2C=CC=CC=2)C2=CC(Cl)=CC=C2N1CC1CC1 MWQCHHACWWAQLJ-UHFFFAOYSA-N 0.000 claims 2
- SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 claims 2
- 229960004538 alprazolam Drugs 0.000 claims 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 claims 2
- 229960000836 amitriptyline Drugs 0.000 claims 2
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims 2
- 229960002519 amoxapine Drugs 0.000 claims 2
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 claims 2
- 229960002729 bromazepam Drugs 0.000 claims 2
- 229960001058 bupropion Drugs 0.000 claims 2
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims 2
- 229960004782 chlordiazepoxide Drugs 0.000 claims 2
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 claims 2
- 229960001403 clobazam Drugs 0.000 claims 2
- CXOXHMZGEKVPMT-UHFFFAOYSA-N clobazam Chemical compound O=C1CC(=O)N(C)C2=CC=C(Cl)C=C2N1C1=CC=CC=C1 CXOXHMZGEKVPMT-UHFFFAOYSA-N 0.000 claims 2
- 229960004606 clomipramine Drugs 0.000 claims 2
- 229960004362 clorazepate Drugs 0.000 claims 2
- XDDJGVMJFWAHJX-UHFFFAOYSA-M clorazepic acid anion Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(C(=O)[O-])N=C1C1=CC=CC=C1 XDDJGVMJFWAHJX-UHFFFAOYSA-M 0.000 claims 2
- 229960003914 desipramine Drugs 0.000 claims 2
- 229960003529 diazepam Drugs 0.000 claims 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims 2
- 229960005426 doxepin Drugs 0.000 claims 2
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 claims 2
- 229960002464 fluoxetine Drugs 0.000 claims 2
- 229960003528 flurazepam Drugs 0.000 claims 2
- SAADBVWGJQAEFS-UHFFFAOYSA-N flurazepam Chemical compound N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F SAADBVWGJQAEFS-UHFFFAOYSA-N 0.000 claims 2
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims 2
- 229960004038 fluvoxamine Drugs 0.000 claims 2
- 229960002158 halazepam Drugs 0.000 claims 2
- 229960004801 imipramine Drugs 0.000 claims 2
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims 2
- 229960004391 lorazepam Drugs 0.000 claims 2
- 229960004090 maprotiline Drugs 0.000 claims 2
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 claims 2
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 claims 2
- 229960001800 nefazodone Drugs 0.000 claims 2
- KJONHKAYOJNZEC-UHFFFAOYSA-N nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 claims 2
- 229960001454 nitrazepam Drugs 0.000 claims 2
- 229960001158 nortriptyline Drugs 0.000 claims 2
- 229960004535 oxazepam Drugs 0.000 claims 2
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 claims 2
- 229960002296 paroxetine Drugs 0.000 claims 2
- 229960000964 phenelzine Drugs 0.000 claims 2
- 229960004856 prazepam Drugs 0.000 claims 2
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 claims 2
- 229960003946 selegiline Drugs 0.000 claims 2
- 229960003188 temazepam Drugs 0.000 claims 2
- 229960003741 tranylcypromine Drugs 0.000 claims 2
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 claims 2
- 229960003991 trazodone Drugs 0.000 claims 2
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 claims 2
- 229960003386 triazolam Drugs 0.000 claims 2
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims 2
- 229960004688 venlafaxine Drugs 0.000 claims 2
- 150000001557 benzodiazepines Chemical class 0.000 abstract description 20
- 229940079593 drug Drugs 0.000 abstract description 15
- 239000003795 chemical substances by application Substances 0.000 abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 239000000556 agonist Substances 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 235000019441 ethanol Nutrition 0.000 description 85
- 238000011282 treatment Methods 0.000 description 21
- 230000001419 dependent effect Effects 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000035622 drinking Effects 0.000 description 7
- 201000009032 substance abuse Diseases 0.000 description 7
- 230000008901 benefit Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 206010063659 Aversion Diseases 0.000 description 5
- 206010002869 Anxiety symptoms Diseases 0.000 description 4
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 231100000566 intoxication Toxicity 0.000 description 4
- 230000035987 intoxication Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010012225 Delirium tremens Diseases 0.000 description 3
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 3
- 208000029650 alcohol withdrawal Diseases 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 229960002069 diamorphine Drugs 0.000 description 3
- 229940085047 disulfiram 250 mg Drugs 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- 208000026251 Opioid-Related disease Diseases 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 208000003443 Unconsciousness Diseases 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 229960002495 buspirone Drugs 0.000 description 2
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 2
- 239000007894 caplet Substances 0.000 description 2
- 229940084440 clonazepam 0.5 mg Drugs 0.000 description 2
- 229940084612 clonazepam 1 mg Drugs 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 206010013663 drug dependence Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 231100000568 intoxicate Toxicity 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 229940121819 ATPase inhibitor Drugs 0.000 description 1
- 206010053164 Alcohol withdrawal syndrome Diseases 0.000 description 1
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 1
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010013496 Disturbance in attention Diseases 0.000 description 1
- 208000003870 Drug Overdose Diseases 0.000 description 1
- 206010013752 Drug withdrawal convulsions Diseases 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 206010016374 Feelings of worthlessness Diseases 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 206010020400 Hostility Diseases 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000005565 Marijuana Use Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010052794 Panic disorder with agoraphobia Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010037180 Psychiatric symptoms Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010043269 Tension headache Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010046542 Urinary hesitation Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000028505 alcohol-related disease Diseases 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 208000004793 anterograde amnesia Diseases 0.000 description 1
- 230000000338 anxiogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical class O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical class C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 description 1
- 229940066010 citalopram 40 mg Drugs 0.000 description 1
- 229940097932 clonazepam 2 mg Drugs 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 231100000725 drug overdose Toxicity 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229940006391 fluoxetine 40 mg Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 208000037870 generalized anxiety Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002673 intoxicating effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 229940080787 lorazepam 1 mg Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000004050 mood stabilizer Substances 0.000 description 1
- 229940127237 mood stabilizer Drugs 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 1
- 229960003086 naltrexone Drugs 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960004872 nizatidine Drugs 0.000 description 1
- SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 description 1
- 229940080131 olanzapine 10 mg Drugs 0.000 description 1
- 239000003401 opiate antagonist Substances 0.000 description 1
- 201000000988 opioid abuse Diseases 0.000 description 1
- 239000000014 opioid analgesic Substances 0.000 description 1
- 229940124636 opioid drug Drugs 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000004799 sedative–hypnotic effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
Definitions
- This invention relates to a combination pharmaceutical medicine that acts in an agonist-aversive manner for people with alcohol related disorders.
- the 5 combination of an agonist such as a benzodiazepine combined with a medicine such as disulfiram or calcium carbimide or naltrexone or acamprosate is used to treat alcohol-associated anxiety and also acts to deter alcohol consumption.
- This invention also relates to aversive medicines combined with other agents to treat medical conditions, which medical conditions or agents' effectiveness are negatively impacted 10 by the consumption of ethanol.
- Anxiety is known to be the predominant complaint of alcohol dependent 20 patients in the first four weeks of early withdrawal from alcohol. Common complaints include tension, difficulty concentrating, fear, fatigue, restlessness and irritability. Other withdrawal symptoms include headaches, insomnia, sweating, tremor, anorexia and dizziness. 3 Many argue that a sub-acute alcohol withdrawal syndrome exists even beyond the four week acute withdrawal period and this 25 withdrawal is responsible for many ongoing complaints of anxiety, insomnia and irritability and depression in abstinent alcohol dependent patients. 4
- benzodiazepines should not be used to treat anxiety or withdrawal complaints in alcohol abusing outpatients.
- Alternative agents such as antidepressants and buspirone are recommended as the therapeutic agents of choice for the complaints of anxiety and insomnia that occur in early withdrawal. These alternative agents are thought to have less of a risk for abuse.
- Current standards of care indicate that if a patient has been treatment resistant to these alternative agents and has ongoing complaints of anxiety a benzodiazepine can still be considered as long as the patient is abstinent from alcohol and stable in their recovery.
- a benzodiazepine is used to treat the anxiety the physician should closely monitor the dose. It is often useful if a family member is included in the therapeutic alliance so that they can provide the alcohol dependent patient with the medicine. 12
- benzodiazepines are often used by patients to intoxicate themselves just as the patient used alcohol to intoxicate himself or herself.
- Short- term side effects include sedation, ataxia, psychomotor slowing, poor concentration and anterograde amnesia.
- Other side effects include impaired driving, increased risk of falls by the elderly and paradoxical effects of increased anger and hostility. 13
- benzodiazepines are consumed with alcohol a more impaired state and possibly lethal state can arise.
- alcohol using patients are treated as outpatients, they are at risk to drink alcohol during treatment with all the subsequent potential dangers a possibility.
- alcohol and benzodiazepines have equivalent intoxicating effects, the co-morbid overuse of the two substances is prevalent. 18
- Disulfiram inhibits aldehyde dehydrogenase, the enzyme that catalyzes the oxidation of acetylaldehyde, a metabolite formed when the body breaks down alcohol.
- aversive reaction includes facial flush, hot flashes, conjunctiva injection, palpitations, headache, and hypotension. It is these negative reactions that are responsible for a patient's aversion to drinking when he or she has ingested disulfiram.
- the most common side effects of the disulfiram without any alcohol having been consumed are drowsiness, headaches and GI discomfort.
- Abstinence occurs when using disulfiram only if there is medication compliance. 21 It is well known to practitioners that patients often do not take their disulfiram so that they can continue drinking alcohol. Compliance rates as low as 20% have been reported. 22 The effectiveness of disulfiram treatment depends on compliance. Methods developed to improve compliance and thus treatment outcomes include behavioral monitoring, group supports, contingency contracting and supervised administration. An advantage of the present invention is that the concurrent administration of the benzodiazepine should also increase compliance.
- Drinking alcohol adversely interacts with many medication treatments, exacerbates many medical illnesses.
- 23 Alcohol use is known to worsens psychiatric symptoms of depression and anxiety. ' Chronic high-dose alcohol use can affect several different organ systems, including the gastrointestinal tract, the cardiovascular system, and the central and peripheral nervous systems. Alcohol-dependent patients also experience higher then average rates of cancer, and lower there life expectancy by 15 years. Thus it is important to design a medication that will effectively treat this serious illness.
- This invention relates to a combination medicine comprising pharmaceutically effective amounts of a first pharmaceutical and a second pharmaceutical, wherein the second pharmaceutical causes illness when alcohol is ingested.
- This invention also relates to a combination medicine comprising pharmaceutically effective amounts of a first pharmaceutical and a second pharmaceutical, wherein the second pharmaceutical blocks the usual effects of alcohol ingestion.
- This invention also relates to a combination medicine comprising pharmaceutically effective amounts of a first pharmaceutical and a second pharmaceutical, wherein the second pharmaceutical is an aldehyde dehydrogenase inhibitor.
- the first and second pharmaceuticals of the combination medicine are intimately co- mixed and may be in any form, such as, capsule, tablet, oral solution, suppository, transdermal patch, sublingual tablet, buccal tablet.
- the first pharmaceutical of the combination medicine is chosen from the following group: anxiolytics, anti-depressants, sedatives, hypnotics, opioids , histamine H2 receptor antagonists, proton pump inhibitors or is chosen to treat the following: anxiety, depression, pain, insomnia, alcohol abuse, drug abuse, epilepsy gastric or duodenal ulcer.
- the invention relates to a combination medicine comprising: benzodiazepine and disulfiram or calcium carbimide; benzodiazepine and acamprosate or naltiexone; anxiolytic and disulfiram or calcium carbimide; anxiolytic and acamprosate or naltiexone; anti-depressant and disulfiram or calcium carbimide; anti-depressant and acamprosate or naltiexone; sedative and disulfiram or calcium carbimide; sedative and acamprosate or naltiexone; hypnotic and disulfiram or calcium carbimide; hypnotic and acamprosate or naltiexone; opioid and disulfiram or calcium carbimide; opioid and acamprosate or naltiexone; histamine H2 receptor antagonist and disulfiram or calcium carbimide; histamine H2 receptor antagonist and acamprosate or naltiexone; proton pump inhibitor and
- This invention relates to a combination medicine comprising a pharmaceutical that has deleterious or reduced effects when alcohol is ingested and disulfiram or calcium carbimide; and a pharmaceutical that has deleterious or reduced effects when alcohol is ingested and acamprosate or naltiexone.
- the combination medicine comprising disulfiram has a quantity of disulfiram of between 10 mg and 1000 mg daily.
- the combination medicine comprising calcium carbimide has a quantity of calcium carbimide of between 5 mg and 500 mg daily.
- the desire to avoid this aversion reaction will encourage the patients to refrain from drinking alcohol.
- the benzodiazepine in turn will treat any underlying anxiety and thus be rewarding in and of itself and also serve to lessen the need for the anxiolytic activity of ethanol. If the combined preparation is taken regularly even missing a dose will create some benzodiazepine withdrawal anxiety that will result in more regular taking of the benzodiazepine-disulfiram combination medicine in order to avoid this withdrawal anxiety.
- Increased compliance ensures that the patient has a sufficient concentration of disulfiram in the body so as to induce an aversion reaction should the patient ingest ethanol.
- the desire to avoid the negative experience associated with the aversion reaction will discourage the patient from ingesting ethyl alcohol.
- the combination medicine of disulfiram combined with a benzodiazepine would be the ideal compound to treat the alcohol dependent patients that complain of anxiety symptoms for which a benzodiazepine is a clinically appropriate treatment.
- This combination medicine could be used to treat early alcohol withdrawal symptoms and chronic anxiety symptoms, provide prophylaxis against seizures and prevent delirium tremens.
- As the combination medicine also contains disulfiram it would prevent the patient from drinking alcohol while taking the benzodiazepine.
- disulfiram it would prevent the patient from drinking alcohol while taking the benzodiazepine.
- a combination of a benzodiazepine with disulfiram treats the underlying condition and reduces the probability of relapse to drinking alcohol.
- the actual ratio of the benzodiazepine to disulfiram will depend on the specific benzodiazepine chosen as well as the severity of the underlying condition for which the benzodiazepine is being used as a treatment. See the table below for a list of benzodiazepines and the probable daily dose.
- the ratio of benzodiazepine to disulfiram is dependent on the benzodiazepine chosen and the daily dose of disulfiram. The ratio can range from as little a 0.00025 milligram of a benzodiazepine to 1 milligram of disulfiram to as much as 4.5 milligram of a benzodiazepine to 1 milligram of disulfiram. Ratios higher or lower than this may also be of therapeutic benefit since the list in the table is not exhaustive of all available benzodiazepines or the daily doses that might be used.
- a young patient may be treated with a high dose of clonazepam during the initial withdrawal from alcohol in order to avoid delirium tremens.
- This patient may be given a combination of 6 mg of clonazepam and 250 mg of disulfiram (ratio of 6/250 or 0.024 mg of clonazepam for every mg of disulfiram) As the patient gets better 2 mg of clonazepam is sufficient to control their anxiety but the amount of disulfiram stays the same (ratio 2/250 or 0.008 mg of clonazepam to 1 mg of disulfiram).
- clonazepam and 62.5 mg of disulfiram may be enough (ratio 0.5/62.5 or 0.004 mg of clonazepam to 1 mg of disulfiram).
- ratio 0.5/62.5 or 0.004 mg of clonazepam to 1 mg of disulfiram The absolute amounts of each drag differ under different clinical circumstances, as do the ratios of the two ingredients with respect to each other.
- the prescription should be only given on a bi-weekly basis.
- a limitation in the prescription availability lessens the chance of the patient consuming a dangerously high amount of disulfiram in order to consume a large amount of the benzodiazepine.
- Dispensing the combination medicine in a weekly amount ameliorates the risk of benzodiazepine overuse.
- the combination medicine must be given in a presentation such that the disulfiram should not be capable of being separated from the benzodiazepine, or at least not be visible to the patient as two separate substances, that is, intimately co- mixed.
- a combination medicine could have both disulfiram and a benzodiazepine present as a finely ground powder of the same colour so that the patient is not capable of separating the disulfiram powder from the benzodiazepine powder. If the powders are of different colour, dyes can be used to mask this difference and make the powders indistinguishable. These powders can then be mixed with excipients so as to be formed into a tablet, caplet or filled into a capsule.
- the combination medicine can also be formulated by dissolving both in a suitable solvent. This solution can then have added to it appropriate types and amounts of excipients to make a pleasant tasting and aesthetically pleasing oral solution.
- a solution containing both ingredients can also be placed in soft gelatine capsules.
- Other presentations could include suppositories, sublingual or buccal tablets, transdermal patches or any other presentation that is capable of delivery the appropriate amount of a benzodiazepine and disulfiram in a form in which the patient is not able to take one without also ingesting or absorbing the other.
- Clonazepam Premix The clonazepam premix of about 160 grams may be prepared as outlined in the table below:
- the two ingredients were mixed together in sufficient quantity to yield the required amount of disulfiram and clonazepam to yield capsules containing the inseparable combination of clonazepam 1 mg and disulfiram 250 mg or 2 mg and disulfiram 250.
- Alcohol dependent insomnia is a state in which even the consumption of moderate amounts of alcohol increases awakenings in the second half of the night. 29 Patients will seek sedatives or hypnotics to treat this type of insomnia. It is often difficult for patients to break the habit of an evening alcoholic or drink or two. For the clinician, prescribing sedatives or hypnotics to such a patient is problematic because the patient may become dependent on the sedative or hypnotic. The real problem is evening time alcohol consumption. Once a pattern of alcohol and sedative hypnotic consumption is established it is very difficult to get a patient off the sedative or hypnotic.
- Non-benzodiazepine examples include zopiclone a cyclopyrrolone derivative, zaleplon a member of the pyrazolopyrimidine class and secobarbital of the barbiturate class.
- Substance abuse often involves multiple substances. For example some patients abuse opioids and alcohol or opioids, cocaine and alcohol. Rehabilitation of opioid dependent persons may involve a methadone maintenance program or maintenance with an anolgue of methadone. Methadone has almost all of the properties of heroin but to blocks the euphoria associated with heroin use. 30 Heroin use may be associated with alcohol abuse and can complicate rehabilitation. A combination of methadone and disulfiram would be usefull in the treatment of patients with both opioid and alcohol abuse. The patient is incented to consume methadone in order to manage their opioid addiction. The concommitant consumption of disulfiram would help the patient avoid alcohol consumption.
- Chronic pain management with opioids may be associated with excessive alcohol consumption. Alcohol acts as a relaxant and also has some analgesic properties. Alcohol abuse can however be a block to rehabilitation.
- a combination opioid analgesic with disulfiram would be helpful in managing the alcohol use and abuse component of the patients clinical situation. The patient would be incented to take the combination medicine inorder to get pain relief and would be discouraged from consuming alcohol because of the disulfiram content of the pain medicine.
- opioids to which disulfiram could be added include methadone, codeine, hydrocodone, hydromorphone, morphine, oxycodone, oxymorphone, pentazocine, meperidine, and propoxyphene.. Many physical conditions are exacerbated if the the patient consumes alcohol.
- Alcohol intake can result in inflammation of the stomach resulting from an increase in gastric acid production and damage to the gastric mucosal barrier. This may exacerbate pain associate with gastric and duodenal ulcers..
- Treatment with agents such as histamine H 2 receptor antagonist and proton pump inhibitors (or H+, K+ ATPase inhibitor) provide the patients with relief of symptoms such as pain.
- histamine H 2 receptor antagonist are cimetidine, famotidine, ranitidine and nizatidine
- examples of a proton pump inhibitor are omeprazole, lansoprazole, rabeprazole, pantoprazole and esomeprazole.
- Combining these agents with disulfiram can result in improved healing of the gasric or duodenal ulcer.
- the patient would be incented to take the combination medicine inorder to get pain relief and would be discouraged from consuming alcohol because of the disulfiram content of the medicine containing a histamine H 2 receptor antagonist or a proton pump
- Disulfiram is of course only one of many aversive medicines available on the market.
- Other medicines that could be substituted for disulfiram in the combination medicines outlined above, to achieve the same fundamental purpose i.e. the reduction of alcohol consumption in a clinical situation in which alcohol complicates the treatment of an undelying illness are calcium carbimide, naltiexone, and acamprosate.
- Calcium carbimide, like disulfiram is an aldehyde dehydrogenase inhibitor.
- Naltiexone is an opioid antagonist and acamprosate interferes with central neurotransmitter effects of alcohol, both of which block the effects of alcohol although the exact mechanism of action is not yet fully understood.
- a benzodiazepine naltiexone combination medicine could contain 1 mg clonazepam and 50 mg of naltiexone. Other strengths of clonazepam may be used. Naltiexone is usually administered at a dose of 50 mg per day.
- Acamprosate clonazepam combination medicine could contain 0.5 mg clonaepam and 666 mg of acamprosate. Such a combination given three time per day would give an effective amount of clonazepam and acamprosate. In other circumstances 1 mg clonazepam and 666 mg of acamprosate given twice daily would also provide an effective amount of both medicines.
- Calcium carbimide clonazepam combination medicine could contain 0.5 mg clonaepam and 100 mg of calcium carbimide. Such a combination given twice a day would give an effective amount of clonazepam and calcium carbimide.
- the above examples relate to treatment of a variety of disease states, addictions and ailments for which alcohol consumption has deleterous effects.
- the invention also relates to the combination of disulfiram, calcium carbimide, naltiexone or acamprosate with another pharmaceutical when that pharmaceutical has deleterious effects or reduced benefits when alcohol is consumed.
- the combination medicine can be comprised of disulfiram, calcium carbimide, naltiexone or acamprosate with a pharmaceutical for the treatment of a disease or condition that is negatively affected by alcohol consumption such as anxiety, depression, pain, insomnia, alcohol abuse, drug abuse, gastric or duodenal ulcer, epilepsy.
- the combination medicine can be comprised of disulfiram, calcium carbimide, naltiexone or acamprosate with a pharmaceutical from the group of anxiolytics, anti-depressants, sedatives, hypnotics, opioids, histamine H2 receptor antagonists, proton pump inhibitors.
- a 43-year-old female suffers from chronic depression, panic disorder with agoraphobia and post-traumatic stress disorder.
- Her alcohol abuse resulted in ineffective psychiatric rehabilitation because it led to drinking and isolation.
- the patient is taking fluoxetine 40 mg, olanzapine 10 mg, clonazepam 0.5 mg during the day and clonazepam 1.5 mg at bed time.
- clonazepam was replaced with the combination medicine consisting of clonazepam 2 mg and disulfiram 250 mg . This combination prevented her from drinking.
- Her anxiety and insomnia improved and she was able to function much better.
- This 42-year-old mother of two has a straggle controlling her drinking and marijuana use. She numbs herself with alcohol and this has resulted in poor self-care. Two months prior to treatment she was admitted to hospital with pneumonia. She is taking citalopram 40 mg and lorazepam 1 mg to manage her chronic dysthymia and generalized anxiety. Two week prior to tieatment she entered a pharmacy in an intoxicated state for a renewal of her benzodiazepine prescription. She was hospitalized for two weeks to detoxify from her bout of alcohol abuse.
- disulfiram-benzodiazepine medicine acts in an agonist-aversive manner that parallels but differs from the agonist-antagonist properties of methadone. If the alcohol itself is the cause of the patient's anxiety symptoms an alcohol induced anxiety disorder is diagnosed. This diagnosis is given whether the anxiety comes on during the intoxication or withdrawal phase of the alcohol. Removal of the alcohol is always the initial intervention. Even if the patient's anxiety were directly caused by alcohol a disulfiram-benzodiazepine pill would be useful for treatment. The disulfiram-benzodiazepine medicine would treat this anxiety at the same time as it prevented the patient from being able to drink comfortably. There are not only short term benefits of this combined medicine but also long term effects of using a benzodiazepine to treat anxiety in an alcohol dependent patient.
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Alcohol disorders have been treated with a variety of therapies, including pharmaceutical. Benzodiazepines, are one type of pharmaceutical that has aided in treating the anxiety associated with alcohol disorders, however there are serious risks of abuse and dependence. Disulfiram is another pharmaceutical that provides a deterrent against consuming alcohol since it causes a person to become very ill when combined with alcohol. The deterrent effect of disulfiram is only effective when taken and non-compliance is a major limitation. This invention relates to a combination pharmaceutical medicine of disulfiram and a benzodiazepine that acts in an agonist-aversive manner for people with alcohol disorders. The combination of disulfiram and a benzodiazepine acts to reduce anxiety and deter alcohol consumption at the same time. This invention also relates to other combinations of agonist and aversive medicines to reduce anxiety and deter alcohol consumption. This invention also relates to aversive medicines combined with other agents to treat medical conditions, which medical conditions or agents' effectiveness are negatively impacted by the consumption of ethanol.
Description
COMBINATIONS OF MEDICAMENTS COMPRISING AN ALCOHOL DETERRENT FOR TREATING ALCOHOL
DEPENDENCE OR ALCOHOL ABUSE
Field of the Invention
This invention relates to a combination pharmaceutical medicine that acts in an agonist-aversive manner for people with alcohol related disorders. The 5 combination of an agonist such as a benzodiazepine combined with a medicine such as disulfiram or calcium carbimide or naltrexone or acamprosate is used to treat alcohol-associated anxiety and also acts to deter alcohol consumption. This invention also relates to aversive medicines combined with other agents to treat medical conditions, which medical conditions or agents' effectiveness are negatively impacted 10 by the consumption of ethanol.
Background of the Invention
Alcohol dependent patients with complaints of anxiety commonly approach physicians for assistance. According to a 1990 study, those with an anxiety disorder had a 50% increase in the odds of being diagnosed with an alcohol disorder.1 15 A 1997 study also indicated a doubling to quadrupling of risk for alcohol and drug dependence given the presence of an anxiety disorder. Rates of anxiety disorders in the alcohol dependent population range from 20-50%. While rates of anxiety disorders in the general population are generally 15-20%.
Anxiety is known to be the predominant complaint of alcohol dependent 20 patients in the first four weeks of early withdrawal from alcohol. Common complaints include tension, difficulty concentrating, fear, fatigue, restlessness and irritability. Other withdrawal symptoms include headaches, insomnia, sweating, tremor, anorexia and dizziness.3 Many argue that a sub-acute alcohol withdrawal syndrome exists even beyond the four week acute withdrawal period and this 25 withdrawal is responsible for many ongoing complaints of anxiety, insomnia and irritability and depression in abstinent alcohol dependent patients.4
Alcohol seems to be anxiolytic while it is being consumed yet anxiogenic over the long term.5 Reducing anxiety symptoms in patients improves alcoholism treatment outcomes6, and ongoing problems with panic and anxiety predict relapse.7 30 Even in prolonged periods of abstinence, alcohol dependent patients claim
incapacitating anxiety as a common reason for return to drinking.8 Benzodiazepines are the easiest way to relieve this anxiety. With their favourable side effect profile and wide therapeutic window, benzodiazepines are the treatment of choice for early withdrawal symptoms. Benzodiazepines also prevent and treat withdrawal seizures and withdrawal induced delirium tremens in patients.
There has been controversy over whether benzodiazepines should be used to treat anxiety symptoms and withdrawal symptoms in alcoholic outpatients. The dangers of dose escalation of the benzodiazepine and combination of the benzodiazepine with alcohol prevent most physicians from using benzodiazepines to treat early alcohol withdrawal symptoms in outpatients. When benzodiazepines are mixed with alcohol, a severe form of intoxication occurs and the mixture of these two substances can lead to blackouts, coma and possibly even death. °
Because of the risk of dual intoxication most experts feel that benzodiazepines should not be used to treat anxiety or withdrawal complaints in alcohol abusing outpatients. Alternative agents such as antidepressants and buspirone are recommended as the therapeutic agents of choice for the complaints of anxiety and insomnia that occur in early withdrawal. These alternative agents are thought to have less of a risk for abuse. Current standards of care indicate that if a patient has been treatment resistant to these alternative agents and has ongoing complaints of anxiety a benzodiazepine can still be considered as long as the patient is abstinent from alcohol and stable in their recovery. n If a benzodiazepine is used to treat the anxiety the physician should closely monitor the dose. It is often useful if a family member is included in the therapeutic alliance so that they can provide the alcohol dependent patient with the medicine.12
The hesitancy to use benzodiazepines in the substance using population is understandable yet unfortunate. Anxiety disorders in the substance using population are notoriously difficult to treat. Anxiety tends to be chronic, with high rates of morbidity and mortality and many agents such as antidepressants, buspirone, neuroleptics or mood stabilizers offer only partial relief.13 There is strong evidence suggesting that anxiety is associated with craving and relapse. And those negative
affective states serve as powerful internal cues that frequently precede relapse. Benzodiazepines are highly effective anxiolytics and patients may benefit greatly from a short course of treatment with subgroups of chronically anxious patients needing long term treatment.14
Despite the known risks of prescribing benzodiazepines to alcohol dependent patients the rates of benzodiazepine use in this population is quite high. One study found that 20% of patients admitted for alcohol detoxification were found by history to have a lifetime history of benzodiazepine abuse or dependence.15 Urine drug screens in that study verified that 40% of patients entering alcohol detoxification programs will have taken benzodiazepines the week prior to admission. Thirty three percent ( 33%) of admissions to ICU's for drug overdoses will have both alcohol and benzodiazepines in their system.16
Unfortunately benzodiazepines are often used by patients to intoxicate themselves just as the patient used alcohol to intoxicate himself or herself. Short- term side effects include sedation, ataxia, psychomotor slowing, poor concentration and anterograde amnesia. Other side effects include impaired driving, increased risk of falls by the elderly and paradoxical effects of increased anger and hostility.13 When benzodiazepines are consumed with alcohol a more impaired state and possibly lethal state can arise. As most alcohol using patients are treated as outpatients, they are at risk to drink alcohol during treatment with all the subsequent potential dangers a possibility. As alcohol and benzodiazepines have equivalent intoxicating effects, the co-morbid overuse of the two substances is prevalent.18
Physicians are used to giving disulfiram to aid patients in their quest to refrain from alcohol. Although 250-500mg of disulfiram is recommended in North America, it appears that some patients may need up to one gram of disulfiram to get a proper aversive reaction to alcohol.19 Although disulfiram is a deterrent medicine that was approved 50 years ago for the treatment of alcoholism, it has unfortunately not consistently been shown to be efficacious.20 Disulfiram inhibits aldehyde dehydrogenase, the enzyme that catalyzes the oxidation of acetylaldehyde, a metabolite formed when the body breaks down alcohol. If alcohol is ingested while
this enzyme is inhibited by disulfiram, blood acetylaldehyde rises causing an aversive reaction. This aversive reaction includes facial flush, hot flashes, conjunctiva injection, palpitations, headache, and hypotension. It is these negative reactions that are responsible for a patient's aversion to drinking when he or she has ingested disulfiram. The most common side effects of the disulfiram without any alcohol having been consumed are drowsiness, headaches and GI discomfort.
Abstinence occurs when using disulfiram only if there is medication compliance.21 It is well known to practitioners that patients often do not take their disulfiram so that they can continue drinking alcohol. Compliance rates as low as 20% have been reported.22 The effectiveness of disulfiram treatment depends on compliance. Methods developed to improve compliance and thus treatment outcomes include behavioral monitoring, group supports, contingency contracting and supervised administration. An advantage of the present invention is that the concurrent administration of the benzodiazepine should also increase compliance.
Drinking alcohol adversely interacts with many medication treatments, exacerbates many medical illnesses.23, 24 Alcohol use is known to worsens psychiatric symptoms of depression and anxiety. ' Chronic high-dose alcohol use can affect several different organ systems, including the gastrointestinal tract, the cardiovascular system, and the central and peripheral nervous systems. Alcohol-dependent patients also experience higher then average rates of cancer, and lower there life expectancy by 15 years. Thus it is important to design a medication that will effectively treat this serious illness.
Summary of the Invention
This invention relates to a combination medicine comprising pharmaceutically effective amounts of a first pharmaceutical and a second pharmaceutical, wherein the second pharmaceutical causes illness when alcohol is ingested.
This invention also relates to a combination medicine comprising pharmaceutically effective amounts of a first pharmaceutical and a second pharmaceutical, wherein the second pharmaceutical blocks the usual effects of alcohol ingestion.
This invention also relates to a combination medicine comprising pharmaceutically effective amounts of a first pharmaceutical and a second pharmaceutical, wherein the second pharmaceutical is an aldehyde dehydrogenase inhibitor.
The first and second pharmaceuticals of the combination medicine are intimately co- mixed and may be in any form, such as, capsule, tablet, oral solution, suppository, transdermal patch, sublingual tablet, buccal tablet.
The first pharmaceutical of the combination medicine is chosen from the following group: anxiolytics, anti-depressants, sedatives, hypnotics, opioids , histamine H2 receptor antagonists, proton pump inhibitors or is chosen to treat the following: anxiety, depression, pain, insomnia, alcohol abuse, drug abuse, epilepsy gastric or duodenal ulcer.
The invention relates to a combination medicine comprising: benzodiazepine and disulfiram or calcium carbimide; benzodiazepine and acamprosate or naltiexone; anxiolytic and disulfiram or calcium carbimide; anxiolytic and acamprosate or naltiexone; anti-depressant and disulfiram or calcium carbimide; anti-depressant and acamprosate or naltiexone; sedative and disulfiram or calcium carbimide; sedative and acamprosate or naltiexone; hypnotic and disulfiram or calcium carbimide; hypnotic and acamprosate or naltiexone; opioid and disulfiram or calcium carbimide; opioid and acamprosate or naltiexone; histamine H2 receptor antagonist and disulfiram or calcium carbimide; histamine H2 receptor antagonist and acamprosate or naltiexone; proton pump inhibitor and disulfiram or calcium carbimide; and proton pump inhibitor and acamprosate or naltiexone.
This invention relates to a combination medicine comprising a pharmaceutical that has deleterious or reduced effects when alcohol is ingested and disulfiram or calcium carbimide; and a pharmaceutical that has deleterious or reduced effects when alcohol is ingested and acamprosate or naltiexone.
The combination medicine comprising disulfiram has a quantity of disulfiram of between 10 mg and 1000 mg daily. The combination medicine comprising calcium carbimide has a quantity of calcium carbimide of between 5 mg and 500 mg daily.
Detailed Description of the Invention
The inventor determined that by combining disulfiram with a benzodiazepine one will improve compliance with the ingestion of disulfiram. The patient knows that disulfiram ingestion will result in an aversion reaction. The desire to avoid this aversion reaction will encourage the patients to refrain from drinking alcohol. The benzodiazepine in turn will treat any underlying anxiety and thus be rewarding in and of itself and also serve to lessen the need for the anxiolytic activity of ethanol. If the combined preparation is taken regularly even missing a dose will create some benzodiazepine withdrawal anxiety that will result in more regular taking of the benzodiazepine-disulfiram combination medicine in order to avoid this withdrawal anxiety. Increased compliance ensures that the patient has a sufficient concentration of disulfiram in the body so as to induce an aversion reaction should the patient ingest ethanol. The desire to avoid the negative experience associated with the aversion reaction will discourage the patient from ingesting ethyl alcohol.
The combination medicine of disulfiram combined with a benzodiazepine would be the ideal compound to treat the alcohol dependent patients that complain of anxiety symptoms for which a benzodiazepine is a clinically appropriate treatment. This combination medicine could be used to treat early alcohol withdrawal symptoms and chronic anxiety symptoms, provide prophylaxis against seizures and prevent delirium tremens. As the combination medicine also contains disulfiram it would prevent the patient from drinking alcohol while taking the benzodiazepine. Thus preventing the toxicity that occurs when benzodiazepines are mixed with alcohol, such as, severe intoxication, blackouts, coma, and possibly even death. A combination of a benzodiazepine with disulfiram treats the underlying condition and reduces the probability of relapse to drinking alcohol.
Prescriptions of small quantities of the combination medicine and frequent contact between the patient and the clinician are also essential to good therapeutic management. Judicious prescribing and careful monitoring can minimize the risk of abuse of the benzodiazepine and allow physicians to educate the patient about risks to their health if they attempt to drink while taking the disulfiram containing combination medicine.
One has to ensure an adequate dose of both medicines is achieved. Even though 250-500mg of disulfiram is recommended in North America, it appears that some patients may need up to one gram of disulfiram to get a proper aversive reaction to alcohol. The proper dose of benzodiazepine is also a contentious subject. Too much benzodiazepine causes over sedation, memory impairment and decreased ability to function cognitively. This includes impaired ability to operated mechanical and electronic equipment, such as motor vehicles etc. Combining disulfiram with various amounts of a benzodiazepine allows the physician to use a benzodiazepine to treat early withdrawal symptoms at the same time as the disulfiram prevents a return to drinking. Thus, there is no risk of the benzodiazepine being mixed with alcohol.
The actual ratio of the benzodiazepine to disulfiram will depend on the specific benzodiazepine chosen as well as the severity of the underlying condition for which the benzodiazepine is being used as a treatment. See the table below for a list of benzodiazepines and the probable daily dose. The ratio of benzodiazepine to disulfiram is dependent on the benzodiazepine chosen and the daily dose of disulfiram. The ratio can range from as little a 0.00025 milligram of a benzodiazepine to 1 milligram of disulfiram to as much as 4.5 milligram of a benzodiazepine to 1 milligram of disulfiram. Ratios higher or lower than this may also be of therapeutic benefit since the list in the table is not exhaustive of all available benzodiazepines or the daily doses that might be used.
For example a young patient may be treated with a high dose of clonazepam during the initial withdrawal from alcohol in order to avoid delirium tremens. This patient may be given a combination of 6 mg of clonazepam and 250 mg of disulfiram (ratio of 6/250 or 0.024 mg of clonazepam for every mg of disulfiram) As the patient gets better 2 mg of clonazepam is sufficient to control their anxiety but the amount of disulfiram stays the same (ratio 2/250 or 0.008 mg of clonazepam to 1 mg of disulfiram). In the treatment of an elderly low body weight patient 0.5 mg of clonazepam and 62.5 mg of disulfiram may be enough (ratio 0.5/62.5 or 0.004 mg of clonazepam to 1 mg of disulfiram). The absolute amounts of each drag differ under different clinical circumstances, as do the ratios of the two ingredients with respect to each other.
To avoid the risk of the patient over-using this combination medicine the prescription should be only given on a bi-weekly basis. A limitation in the prescription availability lessens the chance of the patient consuming a dangerously high amount of disulfiram in order to consume a large amount of the benzodiazepine.
Dispensing the combination medicine in a weekly amount ameliorates the risk of benzodiazepine overuse.
The combination medicine must be given in a presentation such that the disulfiram should not be capable of being separated from the benzodiazepine, or at least not be visible to the patient as two separate substances, that is, intimately co- mixed. For example, a combination medicine could have both disulfiram and a benzodiazepine present as a finely ground powder of the same colour so that the patient is not capable of separating the disulfiram powder from the benzodiazepine powder. If the powders are of different colour, dyes can be used to mask this difference and make the powders indistinguishable. These powders can then be mixed with excipients so as to be formed into a tablet, caplet or filled into a capsule.
The combination medicine can also be formulated by dissolving both in a suitable solvent. This solution can then have added to it appropriate types and amounts of excipients to make a pleasant tasting and aesthetically pleasing oral solution. A solution containing both ingredients can also be placed in soft gelatine capsules. Other presentations could include suppositories, sublingual or buccal tablets, transdermal patches or any other presentation that is capable of delivery the appropriate amount of a benzodiazepine and disulfiram in a form in which the patient is not able to take one without also ingesting or absorbing the other.
Preparation of a disulfiram-benzodiazepine combination medicine Disulfiram Premix Each gram of the disulfiram premix contains
Clonazepam Premix The clonazepam premix of about 160 grams may be prepared as outlined in the table below:
The two ingredients were mixed together in sufficient quantity to yield the required amount of disulfiram and clonazepam to yield capsules containing the inseparable combination of clonazepam 1 mg and disulfiram 250 mg or 2 mg and disulfiram 250.
An example of an alternative formula using the following ingredients is presented below:
Many other formulations for capsules, caplets, tablets, wafers, suspensions and oral liquids will be evident to those skilled in the art of product formulation.
Given that alochol use is a common co-morbid psychiatric disorder of depression, a combination of an antidepressant with disulfiram would treat a patient's depressive state and ensure the abstinence from alcohol. Examples of antidepressants with which disulfiram can be combined are presented below:
This list in not meant to be exhaustive but merely to show examples of antidepressants that could be combined with disulfiram. Treatment with an antidepressant helps the patient overcome feelings of worthlessness and hopelessness. To achieve this benefit from the antidepressant the patient is also required to take the disulfiram as part of the combination disulfiram-antideprssant medicine. The disulfiram in turn discourages the patient from consuming alcohol. Abstinence from alcohol is important in the overall management of depression.
While alcohol can help someone to fall asleep, it also "fragments" the sleep pattern. Alcohol dependent insomnia is a state in which even the consumption of moderate amounts of alcohol increases awakenings in the second half of the night.29 Patients will seek sedatives or hypnotics to treat this type of insomnia. It is often difficult for patients to break the habit of an evening alcoholic or drink or two. For the clinician, prescribing sedatives or hypnotics to such a patient is problematic because the patient may become dependent on the sedative or hypnotic. The real problem is evening time alcohol consumption. Once a pattern of alcohol and sedative
hypnotic consumption is established it is very difficult to get a patient off the sedative or hypnotic. It is also very difficult for a patient to break a long established habit of consuming alcoholic beverages in the evening. Short term treatment with a combination of a suitable sedative or hypnotic with an appropriate amount of dislufiram will give the patient the sleep they desire and help them break their ritualized automatic evening alcohol consumption behaviors. The sedative or hypnotic in this case may be but need not be a member of the benzodiazepine class. Non-benzodiazepine examples include zopiclone a cyclopyrrolone derivative, zaleplon a member of the pyrazolopyrimidine class and secobarbital of the barbiturate class.
Substance abuse often involves multiple substances. For example some patients abuse opioids and alcohol or opioids, cocaine and alcohol. Rehabilitation of opioid dependent persons may involve a methadone maintenance program or maintenance with an anolgue of methadone. Methadone has almost all of the properties of heroin but to blocks the euphoria associated with heroin use.30 Heroin use may be associated with alcohol abuse and can complicate rehabilitation. A combination of methadone and disulfiram would be usefull in the treatment of patients with both opioid and alcohol abuse. The patient is incented to consume methadone in order to manage their opioid addiction. The concommitant consumption of disulfiram would help the patient avoid alcohol consumption.
Chronic pain management with opioids may be associated with excessive alcohol consumption. Alcohol acts as a relaxant and also has some analgesic properties. Alcohol abuse can however be a block to rehabilitation. A combination opioid analgesic with disulfiram would be helpful in managing the alcohol use and abuse component of the patients clinical situation. The patient would be incented to take the combination medicine inorder to get pain relief and would be discouraged from consuming alcohol because of the disulfiram content of the pain medicine. Some examples of opioids to which disulfiram could be added include methadone, codeine, hydrocodone, hydromorphone, morphine, oxycodone, oxymorphone, pentazocine, meperidine, and propoxyphene..
Many physical conditions are exacerbated if the the patient consumes alcohol. Alcohol intake can result in inflammation of the stomach resulting from an increase in gastric acid production and damage to the gastric mucosal barrier. This may exacerbate pain associate with gastric and duodenal ulcers.. Treatment with agents such as histamine H2 receptor antagonist and proton pump inhibitors (or H+, K+ ATPase inhibitor) provide the patients with relief of symptoms such as pain. Examples of histamine H2 receptor antagonist are cimetidine, famotidine, ranitidine and nizatidine and examples of a proton pump inhibitor are omeprazole, lansoprazole, rabeprazole, pantoprazole and esomeprazole. Combining these agents with disulfiram can result in improved healing of the gasric or duodenal ulcer. The patient would be incented to take the combination medicine inorder to get pain relief and would be discouraged from consuming alcohol because of the disulfiram content of the medicine containing a histamine H2 receptor antagonist or a proton pump inhibitor.
Disulfiram is of course only one of many aversive medicines available on the market. Other medicines that could be substituted for disulfiram in the combination medicines outlined above, to achieve the same fundamental purpose i.e. the reduction of alcohol consumption in a clinical situation in which alcohol complicates the treatment of an undelying illness, are calcium carbimide, naltiexone, and acamprosate. Calcium carbimide, like disulfiram is an aldehyde dehydrogenase inhibitor. Naltiexone is an opioid antagonist and acamprosate interferes with central neurotransmitter effects of alcohol, both of which block the effects of alcohol although the exact mechanism of action is not yet fully understood.
A benzodiazepine naltiexone combination medicine could contain 1 mg clonazepam and 50 mg of naltiexone. Other strengths of clonazepam may be used. Naltiexone is usually administered at a dose of 50 mg per day. Acamprosate clonazepam combination medicine could contain 0.5 mg clonaepam and 666 mg of acamprosate. Such a combination given three time per day would give an effective amount of clonazepam and acamprosate. In other circumstances 1 mg clonazepam and 666 mg of acamprosate given twice daily would also provide an effective amount of both medicines. Calcium carbimide clonazepam combination medicine could contain 0.5 mg clonaepam and 100 mg of calcium carbimide. Such a combination
given twice a day would give an effective amount of clonazepam and calcium carbimide.
The above examples relate to treatment of a variety of disease states, addictions and ailments for which alcohol consumption has deleterous effects. The invention also relates to the combination of disulfiram, calcium carbimide, naltiexone or acamprosate with another pharmaceutical when that pharmaceutical has deleterious effects or reduced benefits when alcohol is consumed.
The combination medicine can be comprised of disulfiram, calcium carbimide, naltiexone or acamprosate with a pharmaceutical for the treatment of a disease or condition that is negatively affected by alcohol consumption such as anxiety, depression, pain, insomnia, alcohol abuse, drug abuse, gastric or duodenal ulcer, epilepsy. The combination medicine can be comprised of disulfiram, calcium carbimide, naltiexone or acamprosate with a pharmaceutical from the group of anxiolytics, anti-depressants, sedatives, hypnotics, opioids, histamine H2 receptor antagonists, proton pump inhibitors.
Example No. One
A 43-year-old female suffers from chronic depression, panic disorder with agoraphobia and post-traumatic stress disorder. Her alcohol abuse resulted in ineffective psychiatric rehabilitation because it led to drinking and isolation.
The patient is taking fluoxetine 40 mg, olanzapine 10 mg, clonazepam 0.5 mg during the day and clonazepam 1.5 mg at bed time. In order to control her drinking her clonazepam was replaced with the combination medicine consisting of clonazepam 2 mg and disulfiram 250 mg . This combination prevented her from drinking. Her anxiety and insomnia improved and she was able to function much better.
Example No. Two
This 42-year-old mother of two has a straggle controlling her drinking and marijuana use. She numbs herself with alcohol and this has resulted in poor self-care. Two months prior to treatment she was admitted to hospital with pneumonia. She is taking
citalopram 40 mg and lorazepam 1 mg to manage her chronic dysthymia and generalized anxiety. Two week prior to tieatment she entered a pharmacy in an intoxicated state for a renewal of her benzodiazepine prescription. She was hospitalized for two weeks to detoxify from her bout of alcohol abuse.
While in hospital the patient was started on a clonazepam 1 mg and disulfiram 250 mg combination medicine. At discharge she was given a clonazepam 0.5 mg and disulfiram 125 mg combination medicine. On this medicine she has been able to control her urges to drink. As a result she has been able to improve her relationship with her husband and to re-enter the work force. After 2 months of use, her complete blood count was normal as were her liver and renal function tests. Her urine tested negative for drugs of abuse. Five months after initiation of the combination clonazepam disulfiram combination medicine the patient remains on drag and is doing well.
Here we see this combination disulfiram-benzodiazepine medicine acts in an agonist-aversive manner that parallels but differs from the agonist-antagonist properties of methadone. If the alcohol itself is the cause of the patient's anxiety symptoms an alcohol induced anxiety disorder is diagnosed. This diagnosis is given whether the anxiety comes on during the intoxication or withdrawal phase of the alcohol. Removal of the alcohol is always the initial intervention. Even if the patient's anxiety were directly caused by alcohol a disulfiram-benzodiazepine pill would be useful for treatment. The disulfiram-benzodiazepine medicine would treat this anxiety at the same time as it prevented the patient from being able to drink comfortably. There are not only short term benefits of this combined medicine but also long term effects of using a benzodiazepine to treat anxiety in an alcohol dependent patient.
Various embodiments of the present invention having been thus described in detail by way of example, it will be apparent to those skilled in the art that variations and modifications may be made without departing from the invention. The invention includes all such variations and modifications as fall within the scope of the appended claims.
References
1. Regier, D. A., M. E. Farmer, et al. (1990). "Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study." Jama 264(19): 2511-8.
2. Kessler, R. C, R. M. Cram, et al. (1997). "Lifetime co-occurrence of DSM-UI-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey." Arch Gen Psychiatry 54(4): 313-21.
3. Sellers, E. M. (1988). "Alcohol, barbiturate and benzodiazepine withdrawal syndromes: clinical management." Cmai 139(2): 113-20.
4. Romach, M. K. and E. M. Sellers (1991). "Management of the alcohol withdrawal syndrome." Annu Rev Med 42: 323-40.
5. Kushner, M. G., K. Abrams, et al. (2000). "The relationship between anxiety disorders and alcohol use disorders: a review of major perspectives and findings." Clin Psvchol Rev 20(2 : 149-71.
6. Fals-Stewart, W. and J. Schafer (1992). "The treatment of substance abusers diagnosed with obsessive-compulsive disorder: an outcome study." J Subst Abuse Treat 9(4): 365-70.
7. LaBounty, L. P., D. Hatsukami, et al. (1992). "Relapse among alcoholics with phobic and panic symptoms." Addict Behav 17(1): 9-15.
8. Tomasson, K. and P. Vaglum (1996). "Psychopathology and alcohol consumption among treatment-seeking alcoholics: a prospective study." Addiction 91(7): 1019- 30.
9. Nunes, E. V., P. J. McGrath, et al. (1995). "Treating anxiety in patients with alcoholism." J Clin Psychiatry 56(Suppl 2): 3-9.
10. Benzodiazepine Dependence, Toxicity, and Abuse: A Task Force report of the American Psychiatric Association. Washington, DC: APA; 1990.
11. Frances, R. J. and L. Borg (1993). "The tieatment of anxiety in patients with
alcoholism." J Clin Psychiatry 54 Suppl: 37-43.
12. DuPont, R. L., Saylor, K.E. Sedative/Hypnotics and benzodiazepines. In: Frances RJ, Miller SI, eds. Clinical Textbook of Addictive Disorders. New York, NY Guilford Press 1991:69-102.
13. Posternak, M. A. and T. I. Mueller (2001). "Assessing the risks and benefits of benzodiazepines for anxiety disorders in patients with a history of substance abuse or dependence." Am J Addict 10(1): 48-68.
14. Rickels, K. (1983). "Nonbenzodiazepine anxiolytics: clinical usefulness." J Clin Psychiatry 44(11 Pt 2): 38-44.
15. Ross, HE. (1993) "Benzodiazepine use and anxiolytic abuse and dependence in treated alcoholics" Addiction 88:209-218.
16. Chan, A.K. (1984) "Effects of Combined Alcohol and Benzodiazepines: a Review" Drug and Alcohol Dependence 13:315-341.
17. Ciraulo, D. A., B. F. Sands, et al. (1988). "Critical review of liability for benzodiazepine abuse among alcoholics." Am J Psychiatry 145(12): 1501-6.
18. Sussman, N. (1993). "Treating anxiety while minimizing abuse and dependence." J Clin Psychiatry 54 Suppl: 44-51.
19. Brewer, C. (1984). "How effective is the standard dose of disulfiram? A review of the alcohol-disulfiram reaction in practice." Br J Psychiatry 144: 200-2.
20. Kranzler, H. R. (2000). "Pharmacotherapy of alcoholism: gaps in knowledge and opportunities for research." Alcohol Alcohol 35(6): 537-47.
21. Kristenson, H. (1995). "How to get the best out of antabuse." Alcohol Alcohol 30(6): 775-83.
22. Fuller, R. K., L. Branchey, et al. (1986). "Disulfiram tieatment of alcoholism. A Veterans Administration cooperative study." Jama 256(11): 1449-55.
23. Blow, F.C. (2000) "Treatment of Older Women with Alcohol Problems: Meeting the Challenge for a Special Population." Alcohol Clin Exp Res 24:1257-66.
24. Alcohol and Alcoholism. Page 2562 Harrison's Principles of Internal Medicine 15th Edition 2001 McGraw-Hill Toronto.
25. Devanand, D.P. (2002) "Comorbid Psychiatric Disorders in Late Life Depression" Biol Psychiatry 52:236-42.
26. Nierenberg, A.A. (2001) "Current Perspectives on the Diagnosis and Treatment of Major Depressive Disorder" Am J Manag Care 7(11 Suppl):S353-66.
27. Benzodiazepine Monograph Page 187 Compendium of Pharmaceuticals and Specialties 2001Thirty-sixth Edition Canadian Pharmacists Association Ottawa Ontario Canada.
28. Compounds Used For Anxiety Page 422. Goodman & Gilman's The Pharmacological Basis of Therapeutics 9 Edition McGraw-Hill Toronto.
29. Medication-, Drug-, or Acohol-Dependant Insomnia. Page 158 Harrison's Principles of Internal Medicine 15th Edition 2001 McGraw-Hill Toronto.
30. Opioid Drug Abuse and Dependence. Page 2569 Harrison's Principles of Internal Medicine 15th Edition 2001 McGraw-Hill Toronto.
Claims
1. A combination medicine comprising pharmaceutically effective amounts of a first pharmaceutical and a second pharmaceutical, wherein the second pharmaceutical causes illness when alcohol is ingested.
2. A combination medicine comprising pharmaceutically effective amounts of a first pharmaceutical and a second pharmaceutical, wherein the second pharmaceutical blocks the usual effects of alcohol ingestion.
3. A combination medicine comprising pharmaceutically effective amounts of a first pharmaceutical and a second pharmaceutical, wherein the second pharmaceutical is an aldehyde dehydrogenase inhibitor.
4. The combination medicine of claims 1, 2 and 3, wherein said first pharmaceutical and second pharmaceutical are intimately co-mixed.
5. The combination medicine of claims 1 , 2 and 3, wherein said combination medicine is in the form of one of the following: capsule, tablet, oral solution, suspension, wafer, suppository, transdermal patch, sublingual tablet, buccal tablet.
6. The combination medicine of claims 1 , 2 and 3, wherein the first pharmaceutical is chosen from the following group: anxiolytics, antidepressants, sedatives, hypnotics, opioids, histamine H2 receptor antagonists, proton pump inhibitors.
7. The combination medicine of claims 1, 2 and 3, wherein the first pharmaceutical treats one of the following: anxiety, depression, pain, insomnia, alcohol abuse, drug abuse, gastric or duodenal ulcer, epilepsy.
8. The combination medicine of claims 1 , 2 and 3, wherein the first pharmaceutical is an anxiolytic.
9. The combination medicine of claim 8, wherein the first pharmaceutical is a benzodiazepine.
10. The combination medicine of claims 1 and 3, wherein the first pharmaceutical is a benzodiazepine and the second pharmaceutical is disulfiram or calcium carbimide.
11. The combination medicine of claim 2, wherein the first pharmaceutical is a benzodiazepine and the second pharmaceutical is acamprosate or naltiexone.
12. The combination medicine of claim 10, wherein the benzodiazepine is chosen from the following: alprazolam, bromazepam, chlordiazepoxide, clobazam, clonazepam, clorazepate, diazepam, flurazepam, halazepam, lorazepam, nitrazepam, oxazepam, prazepam, temazepam, triazolam.
13. The combination medicine of claim 11 , wherein the benzodiazepine is chosen from the following: alprazolam, bromazepam, chlordiazepoxide, clobazam, clonazepam, clorazepate, diazepam, flurazepam, halazepam, lorazepam, nitrazepam, oxazepam, prazepam, temazepam, triazolam.
14. The combination medicine of claims 1, 2 and 3, wherein the first pharmaceutical is an anti-depressant.
15. The combination medicine of claim 14 wherein the said anti-depressant is chosen from the following group: tricyclics, secondary amine tricyclics, serotonin reuptake inhibitors, atypical antidepressants, monoamine oxidase inhibitors.
16. The combination medicine of claims 1 and 3, wherein the first pharmaceutical is chosen from the following group: tricyclics, secondary amine tricyclics, serotonin reuptake inhibitors, atypical antidepressants, monoamine oxidase inhibitors; and the second pharmaceutical is disulfiram or calcium carbimide.
17. The combination medicine of claim 2, wherein the first pharmaceutical is a chosen from the following group: tricyclics, secondary amine tricyclics, serotonin reuptake inhibitors, atypical antidepressants, monoamine oxidase inhibitors; and the second pharmaceutical is acamprosate or naltiexone.
18. The combination medicine of claims 1 and 3, wherein the first pharmaceutical is chosen from the following group: amitriptyline, clomipramine, doxepin, imipramine, amoxapine, desipramine, maprotiline, nortriptyline, fluoxetine, fluvoxamine, paroxetine, sertialine, venlafaxine, bupropion, nefazodone, trazodone, phenelzine, tranylcypromine, selegiline; and the second pharmaceutical is disulfiram or calcium carbimide.
19. The combination medicine of claim 2, wherein the first pharmaceutical is a chosen from the following group: amitriptyline, clomipramine, doxepin, imipramine, amoxapine, desipramine, maprotiline, nortriptyline, fluoxetine, fluvoxamine, paroxetine, sertialine, venlafaxine, bupropion, nefazodone, trazodone, phenelzine, tranylcypromine, selegiline; and the second pharmaceutical is acamprosate or naltiexone.
20. The combination medicine of claims 1, 2 and 3, wherein the first pharmaceutical is a sedative.
21. The combination medicine of claim 20 wherein the said sedative is chosen from the following group: benzodiazepine, cyclopyrrolone derivatives, pyrazolopyrimidines, barbiturates, zopiclone, zaleplon, secobarbital.
22. The combination medicine of claims 1 and 3, wherein the first pharmaceutical is chosen from the following group: benzodiazepine, cyclopyrrolone derivatives, pyrazolopyrimidines, barbiturates, zopiclone, zaleplon, secobarbital; and the second pharmaceutical is disulfiram or calcium carbimide.
23. The combination medicine of claim 2, wherein the first pharmaceutical is a chosen from the following group: benzodiazepine, cyclopyrrolone derivatives, pyrazolopyrimidines, barbiturates, zopiclone, zaleplon, secobarbital; and the second pharmaceutical is acamprosate or naltiexone.
24. The combination medicine of claims 1, 2 and 3, wherein the first pharmaceutical is a hypnotic.
25. The combination medicine of claim 24 wherein the said hypnotic is chosen from the following group: benzodiazepine, cyclopyrrolone derivatives, pyrazolopyrimidines, barbiturates, zopiclone, zaleplon, secobarbital.
26. The combination medicine of claims 1 and 3, wherein the first pharmaceutical is chosen from the following group: benzodiazepine, cyclopyrrolone derivatives, pyrazolopyrimidines, barbiturates, zopiclone, zaleplon, secobarbital; and the second pharmaceutical is disulfiram or calcium carbimide.
27. The combination medicine of claim 2, wherein the first pharmaceutical is a chosen from the following group: benzodiazepine, cyclopyrrolone derivatives, pyrazolopyrimidines, barbiturates, zopiclone, zaleplon, secobarbital; and the second pharmaceutical is acamprosate or naltiexone.
28. The combination medicine of claims 1, 2 and 3, wherein the first pharmaceutical is an opioid.
29. The combination medicine of claim 28 wherein the said opioid is chosen from the following group: methadone, codeine, hydrocodone, hydromorphone, morphine, oxycodone, oxymorphone, pentazocine, meperidine, propoxyphene.
30. The combination medicine of claims 1 and 3, wherein the first pharmaceutical is chosen from the following group: methadone, codeine, hydrocodone, hydromorphone, morphine, oxycodone, oxymorphone, pentazocine, meperidine, propoxyphene; and the second pharmaceutical is disulfiram or calcium carbimide.
31. The combination medicine of claim 2, wherein the first pharmaceutical is a chosen from the following group: methadone, codeine, hydrocodone, hydromorphone, morphine, oxycodone, oxymorphone, pentazocine, meperidine, propoxyphene; and the second pharmaceutical is acamprosate or naltiexone.
32. The combination medicine of claims 1, 2 and 3, wherein the first pharmaceutical is a histamine H2 receptor antagonist.
33. The combination medicine of claim 32 wherein the said histamine H2 receptor antagonist is chosen from the following group: cimetidine, ranitidine or famotidine.
34. The combination medicine of claims 1 and 3, wherein the first pharmaceutical is chosen from the following group: cimetidine ranitidine or famotidine; and the second pharmaceutical is disulfiram or calcium carbimide.
35. The combination medicine of claim 2, wherein the first pharmaceutical is a chosen from the following group: cimetidine ranitidine or famotidine; and the second pharmaceutical is acamprosate or naltiexone.
36. The combination medicine of claims 1, 2 and 3, wherein the first pharmaceutical is a proton pump inhibitor.
37. The combination medicine of claim 36 wherein the said proton pump inhibitor is chosen from the following group: omeprazole, lansoprazole, rabeprazole, pantoprazole or esomeprazole.
38. The combination medicine of claims 1 and 3, wherein the first pharmaceutical is chosen from the following group: omeprazole , lansoprazole, rabeprazole, pantoprazole or esomeprazole.; and the second pharmaceutical is disulfiram or calcium carbimide.
39. The combination medicine of claim 2, wherein the first pharmaceutical is a chosen from the following group: omeprazole , lansoprazole, rabeprazole, pantoprazole or esomeprazole; and the second pharmaceutical is acamprosate or naltiexone.
40. The combination medicine of claims 1, 2 and 3, wherein the first pharmaceutical has deleterious or reduced effects when alcohol is ingested.
41. The combination medicine of claims 1 and 3, wherein the first pharmaceutical has deleterious or reduced effects when alcohol is ingested and the second pharmaceutical is disulfiram or calcium carbimide.
42. The combination medicine of claim 2, wherein the first pharmaceutical has deleterious or reduced effects when alcohol is ingested and the second pharmaceutical is acamprosate or naltiexone.
43. The combination medicine of claims 10, 16, 18, 22, 26, 30, 34, 38 and 41 , wherein the pharmaceutically effective amount of disulfiram is between 10 mg and 1000 mg daily.
44. The combination medicine of claims 10, 16, 18, 22, 26, 30, 34, 38 and 41, wherein the pharmaceutically effective amount of disulfiram is between 250 mg and 500 mg daily.
45. The combination medicine of claims 10, 16, 18, 22, 26, 30, 34, 38 and 41, wherein the pharmaceutically effective amount of calcium carbimide is between 5 and 500 mg daily.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2003303015A AU2003303015A1 (en) | 2002-12-17 | 2003-06-25 | Combinations of medicaments comprising an alcohol deterrent for treating alcohol dependence or alcohol abuse |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002414500A CA2414500A1 (en) | 2002-12-17 | 2002-12-17 | Agonist-aversive combination medicines |
| CA2,414,500 | 2002-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2004054570A1 true WO2004054570A1 (en) | 2004-07-01 |
Family
ID=32514058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CA2003/000990 WO2004054570A1 (en) | 2002-12-17 | 2003-06-25 | Combinations of medicaments comprising an alcohol deterrent for treating alcohol dependence or alcohol abuse |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU2003303015A1 (en) |
| CA (1) | CA2414500A1 (en) |
| WO (1) | WO2004054570A1 (en) |
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2289405C2 (en) * | 2005-03-18 | 2006-12-20 | МУЗ городская клиническая больница № 3 им. М.А. Подгорбунского г.Кемерово | Method for treatment of alcoholic delirium |
| WO2008045641A3 (en) * | 2006-10-10 | 2008-11-20 | Univ Chicago | Composition s comprising a benzodiazepine, an alcohol aversive agent and an abuse aversive agent |
| US8486449B2 (en) | 2008-12-16 | 2013-07-16 | Paladin Labs Inc. | Misuse preventative, controlled release formulation |
| US8486448B2 (en) | 2007-12-17 | 2013-07-16 | Paladin Labs Inc. | Misuse preventative, controlled release formulation |
| JP2013536837A (en) * | 2010-09-01 | 2013-09-26 | トニックス ファーマスーティカルズ，インコーポレイテッド | Treatment of addiction to cocaine |
| EP2705843A1 (en) * | 2012-09-05 | 2014-03-12 | Pharnext | Therapeutic approaches for treating epilepsy and related disorders through reduction of epileptogenesis |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| US9125868B2 (en) | 2006-11-09 | 2015-09-08 | Orexigen Therapeutics, Inc. | Methods for administering weight loss medications |
| US9248123B2 (en) | 2010-01-11 | 2016-02-02 | Orexigen Therapeutics, Inc. | Methods of providing weight loss therapy in patients with major depression |
| US9457005B2 (en) | 2005-11-22 | 2016-10-04 | Orexigen Therapeutics, Inc. | Compositions and methods for increasing insulin sensitivity |
| US9633575B2 (en) | 2012-06-06 | 2017-04-25 | Orexigen Therapeutics, Inc. | Methods of treating overweight and obesity |
| US10238647B2 (en) | 2003-04-29 | 2019-03-26 | Nalpropion Pharmaceuticals, Inc. | Compositions for affecting weight loss |
| CN110420190A (en) * | 2019-08-29 | 2019-11-08 | 湖南洞庭药业股份有限公司 | Clonazepam tablet and preparation method thereof |
| CN111420062A (en) * | 2020-04-29 | 2020-07-17 | 漳州卫生职业学院 | Synergistic agent for benzodiazepine drugs |
| WO2022016097A1 (en) * | 2020-07-16 | 2022-01-20 | Musc Foundation For Research Development | G9a inhibition decreases stress-induced and dependence-induced escalation of alcohol drinking |
| WO2022086835A1 (en) * | 2020-10-19 | 2022-04-28 | Presti Michael | Combination products to mitigate the risk of non-benzodiazepine benzodiazepine agonist adverse reaction and overdose |
| US11324741B2 (en) | 2008-05-30 | 2022-05-10 | Nalpropion Pharmaceuticals Llc | Methods for treating visceral fat conditions |
| US20220193104A1 (en) * | 2019-05-05 | 2022-06-23 | Guangzhou Century Clinical Research Co., Ltd | Compound for regulating body weight imbalance, composition thereof and application thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10478408B2 (en) | 2018-01-26 | 2019-11-19 | Michael Presti | Combination treatments for opioid crisis |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873076A (en) * | 1988-04-29 | 1989-10-10 | Baker Cummins Pharmaceuticals, Inc. | Method of safely providing anesthesia or conscious sedation |
| WO1992005787A1 (en) * | 1990-10-01 | 1992-04-16 | Radecki Thomas E | Drug therapy for alcohol abusers |
| US6034091A (en) * | 1993-03-02 | 2000-03-07 | John S. Nagle | Method for treating emotional or mental illness and emotional or mental illness concomitant with seizures |
-
2002
- 2002-12-17 CA CA002414500A patent/CA2414500A1/en not_active Abandoned
-
2003
- 2003-06-25 WO PCT/CA2003/000990 patent/WO2004054570A1/en not_active Application Discontinuation
- 2003-06-25 AU AU2003303015A patent/AU2003303015A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873076A (en) * | 1988-04-29 | 1989-10-10 | Baker Cummins Pharmaceuticals, Inc. | Method of safely providing anesthesia or conscious sedation |
| WO1992005787A1 (en) * | 1990-10-01 | 1992-04-16 | Radecki Thomas E | Drug therapy for alcohol abusers |
| US6034091A (en) * | 1993-03-02 | 2000-03-07 | John S. Nagle | Method for treating emotional or mental illness and emotional or mental illness concomitant with seizures |
Non-Patent Citations (5)
| Title |
|---|
| ANONYMOUS: "VII Conference on Ethanol-Drugs Interaction and Pharmacological Treatment of Alcohol-Dependence, Lodz, Poland, 2 June 1995", POLISH JOURNAL OF PHARMACOLOGY, vol. 47, no. 6, 1995, pages 547 - 555, XP009018987, ISSN: 1230-6002 * |
| BOYARSKY B K ET AL: "Improving the quality of substance dependency treatment with pharmacotherapy", SUBSTANCE USE AND MISUSE 2000 UNITED STATES, vol. 35, no. 12-14, 2000, pages 2095 - 2125, XP009018985, ISSN: 1082-6084 * |
| HELANDER ANDERS ET AL: "Effects of Benzodiazepines on Aldehyde Dehydrogenase Activity", ALCOHOL, vol. 12, no. 5, 1995, pages 413 - 415, XP002258260, ISSN: 0741-8329 * |
| PEACHEY J E ET AL: "The role of drugs in the treatment of alcoholism.", DRUGS. AUSTRALIA FEB 1984, vol. 27, no. 2, February 1984 (1984-02-01), pages 171 - 182, XP009019008, ISSN: 0012-6667 * |
| SELLERS E M ET AL: "Differential effects of benzodiazepine disposition by disulfiram and ethanol.", ARZNEIMITTEL-FORSCHUNG. GERMANY, WEST 1980, vol. 30, no. 5a, 1980, pages 882 - 886, XP001155550, ISSN: 0004-4172 * |
Cited By (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10238647B2 (en) | 2003-04-29 | 2019-03-26 | Nalpropion Pharmaceuticals, Inc. | Compositions for affecting weight loss |
| RU2289405C2 (en) * | 2005-03-18 | 2006-12-20 | МУЗ городская клиническая больница № 3 им. М.А. Подгорбунского г.Кемерово | Method for treatment of alcoholic delirium |
| US9457005B2 (en) | 2005-11-22 | 2016-10-04 | Orexigen Therapeutics, Inc. | Compositions and methods for increasing insulin sensitivity |
| US9107837B2 (en) | 2006-06-05 | 2015-08-18 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| WO2008045641A3 (en) * | 2006-10-10 | 2008-11-20 | Univ Chicago | Composition s comprising a benzodiazepine, an alcohol aversive agent and an abuse aversive agent |
| US9125868B2 (en) | 2006-11-09 | 2015-09-08 | Orexigen Therapeutics, Inc. | Methods for administering weight loss medications |
| US8486448B2 (en) | 2007-12-17 | 2013-07-16 | Paladin Labs Inc. | Misuse preventative, controlled release formulation |
| US8691270B2 (en) | 2007-12-17 | 2014-04-08 | Paladin Labs Inc. | Misuse preventative, controlled release formulation |
| US8920834B2 (en) | 2007-12-17 | 2014-12-30 | Paladin Labs Inc. | Misuse preventative, controlled release formulation |
| US8920833B2 (en) | 2007-12-17 | 2014-12-30 | Paladin Labs Inc. | Misuse preventative, controlled release formulation |
| US11324741B2 (en) | 2008-05-30 | 2022-05-10 | Nalpropion Pharmaceuticals Llc | Methods for treating visceral fat conditions |
| US8685447B2 (en) | 2008-12-16 | 2014-04-01 | Paladin Labs Inc. | Misuse preventative, controlled release formulation |
| US8927013B2 (en) | 2008-12-16 | 2015-01-06 | Paladin Labs Inc. | Misuse preventative, controlled release formulation |
| US8486449B2 (en) | 2008-12-16 | 2013-07-16 | Paladin Labs Inc. | Misuse preventative, controlled release formulation |
| US8927014B2 (en) | 2008-12-16 | 2015-01-06 | Paladin Labs Inc. | Misuse preventative, controlled release formulation |
| US9248123B2 (en) | 2010-01-11 | 2016-02-02 | Orexigen Therapeutics, Inc. | Methods of providing weight loss therapy in patients with major depression |
| US10322121B2 (en) | 2010-01-11 | 2019-06-18 | Nalpropion Pharmaceuticals, Inc. | Methods of providing weight loss therapy in patients with major depression |
| JP2013536837A (en) * | 2010-09-01 | 2013-09-26 | トニックス ファーマスーティカルズ，インコーポレイテッド | Treatment of addiction to cocaine |
| US10403170B2 (en) | 2012-06-06 | 2019-09-03 | Nalpropion Pharmaceuticals, Inc. | Methods of treating overweight and obesity |
| US9633575B2 (en) | 2012-06-06 | 2017-04-25 | Orexigen Therapeutics, Inc. | Methods of treating overweight and obesity |
| EP2705843A1 (en) * | 2012-09-05 | 2014-03-12 | Pharnext | Therapeutic approaches for treating epilepsy and related disorders through reduction of epileptogenesis |
| WO2014037417A1 (en) * | 2012-09-05 | 2014-03-13 | Pharnext | Therapeutic approaches for treating epilepsy and related disorders through reduction of epileptogenesis |
| US20220193104A1 (en) * | 2019-05-05 | 2022-06-23 | Guangzhou Century Clinical Research Co., Ltd | Compound for regulating body weight imbalance, composition thereof and application thereof |
| US12274710B2 (en) * | 2019-05-05 | 2025-04-15 | Guangzhou Century Clinical Research Co., Ltd | Compound for regulating body weight imbalance, composition thereof and application thereof |
| CN110420190A (en) * | 2019-08-29 | 2019-11-08 | 湖南洞庭药业股份有限公司 | Clonazepam tablet and preparation method thereof |
| CN110420190B (en) * | 2019-08-29 | 2021-07-09 | 湖南洞庭药业股份有限公司 | Clonazepam tablets and preparation method thereof |
| CN111420062A (en) * | 2020-04-29 | 2020-07-17 | 漳州卫生职业学院 | Synergistic agent for benzodiazepine drugs |
| WO2022016097A1 (en) * | 2020-07-16 | 2022-01-20 | Musc Foundation For Research Development | G9a inhibition decreases stress-induced and dependence-induced escalation of alcohol drinking |
| WO2022086835A1 (en) * | 2020-10-19 | 2022-04-28 | Presti Michael | Combination products to mitigate the risk of non-benzodiazepine benzodiazepine agonist adverse reaction and overdose |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003303015A1 (en) | 2004-07-09 |
| CA2414500A1 (en) | 2004-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004054570A1 (en) | Combinations of medicaments comprising an alcohol deterrent for treating alcohol dependence or alcohol abuse | |
| RU2281771C2 (en) | Use of dextromethorphan and oxidase inhibitor for removing addiction to narcotics and antidepressants in patients | |
| US8012958B2 (en) | Methods for treating anxiety related disorders | |
| Nikolaus et al. | Pharmacological treatments for persistent non-malignant pain in older persons | |
| Halpern | Analgesic drugs in the management of pain | |
| TWI313598B (en) | Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines | |
| US6344487B1 (en) | Treatment of insomnia | |
| JP2007529550A (en) | How to treat alcoholism | |
| US6395727B1 (en) | Method of treating Bulimia Nervosa and related eating disorders by administration of atypical antipsychotic medications | |
| CN101272683A (en) | Methods for the treatment of substance abuse and dependence | |
| Foral et al. | Insomnia: a therapeutic review for pharmacists | |
| Habibi et al. | Hydrocodone and Acetaminophen | |
| BR112019010077A2 (en) | therapies for the treatment of hypokalemic conditions and lidocaine ineffectiveness | |
| Carney et al. | Palliative care and end-of-life issues | |
| Yeo et al. | Oral agents for the management of agitation and agitated delirium in critically ill patients | |
| Schifano | Drug abuse: treatment and management | |
| Sinclair | Drugs for alcohol dependence | |
| US20070142367A1 (en) | Method and medicine for treating gastrointestinal disorder including fecal incontinence | |
| Ciraulo et al. | The pharmacology of nonalcohol sedative hypnotics | |
| ULC | Anxiolytic-Antipanic | |
| Sinclair | Drugs for alcohol dependence | |
| Kröll et al. | 11 Pre-operative anxiety, stress and pre-medication | |
| Nazari et al. | Unusual route of buprenorphine administration: an alternative approach for bypassing adverse drug reactions | |
| Vanni et al. | Pharmacological Pain Management Strategies | |
| Aguilar | Developing Choice: Issues and Implications of the Operant-Choice Mouse Model |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: JP |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |